Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Lowered to Sell at StockNews.com

Oramed Pharmaceuticals (NASDAQ:ORMP) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.

Oramed Pharmaceuticals Price Performance

Shares of NASDAQ ORMP opened at $2.22 on Wednesday. The company has a 50 day simple moving average of $2.34 and a 200 day simple moving average of $2.36. The firm has a market cap of $89.49 million, a PE ratio of 20.18 and a beta of 1.66. Oramed Pharmaceuticals has a 1 year low of $2.00 and a 1 year high of $3.67.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ORMP. World Equity Group Inc. bought a new position in Oramed Pharmaceuticals in the 4th quarter valued at approximately $48,000. XTX Topco Ltd raised its holdings in Oramed Pharmaceuticals by 59.7% in the 3rd quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company’s stock valued at $60,000 after buying an additional 9,242 shares during the last quarter. Marquette Asset Management LLC bought a new position in Oramed Pharmaceuticals in the 4th quarter valued at approximately $81,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Oramed Pharmaceuticals during the 3rd quarter valued at approximately $272,000. Finally, Dimensional Fund Advisors LP increased its position in Oramed Pharmaceuticals by 143.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company’s stock valued at $288,000 after purchasing an additional 70,190 shares during the period. Institutional investors own 12.73% of the company’s stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.